Cargando…

Hypereosinophilic syndrome presenting as coagulopathy

BACKGROUND: Hypereosinophilic syndrome (HES) is an extremely uncommon group of disorders. It rarely presents with coagulopathy without cardiac involvement. CASE PRESENTATION: A 33-year-old previously healthy male with no history of atopic disease presented with abdominal pain, hematochezia, peripher...

Descripción completa

Detalles Bibliográficos
Autores principales: Aukstuolis, Kestutis, Cooper, Jocelyn J., Altman, Katherine, Lang, Anna, Ayars, Andrew G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941788/
https://www.ncbi.nlm.nih.gov/pubmed/35317854
http://dx.doi.org/10.1186/s13223-022-00666-2
_version_ 1784673174702522368
author Aukstuolis, Kestutis
Cooper, Jocelyn J.
Altman, Katherine
Lang, Anna
Ayars, Andrew G.
author_facet Aukstuolis, Kestutis
Cooper, Jocelyn J.
Altman, Katherine
Lang, Anna
Ayars, Andrew G.
author_sort Aukstuolis, Kestutis
collection PubMed
description BACKGROUND: Hypereosinophilic syndrome (HES) is an extremely uncommon group of disorders. It rarely presents with coagulopathy without cardiac involvement. CASE PRESENTATION: A 33-year-old previously healthy male with no history of atopic disease presented with abdominal pain, hematochezia, peripheral eosinophilia as high as 10,000 eos/µL, right and left portal vein, mesenteric, and splenic vein thrombi with ischemic colitis resulting in hemicolectomy and small bowel resection. Despite an extensive workup for primary and secondary etiologies of hypereosinophilia by hematology/oncology, infectious disease, rheumatology and allergy/immunology, no other clear causes were identified, and the patient was diagnosed with idiopathic HES. His eosinophilia was successfully treated with high-dose oral corticosteroids (OCS) and subsequently transitioned to anti-IL-5-receptor therapy with benralizumab. He has continued this treatment for over a year with no recurrence of eosinophilia or thrombosis while on benralizumab. CONCLUSION: In patients with an unexplained coagulopathy and eosinophilia, eosinophilic disorders such as HES should be considered. Corticosteroid-sparing agents, such as benralizumab show promise for successfully treating these patients.
format Online
Article
Text
id pubmed-8941788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89417882022-03-24 Hypereosinophilic syndrome presenting as coagulopathy Aukstuolis, Kestutis Cooper, Jocelyn J. Altman, Katherine Lang, Anna Ayars, Andrew G. Allergy Asthma Clin Immunol Case Report BACKGROUND: Hypereosinophilic syndrome (HES) is an extremely uncommon group of disorders. It rarely presents with coagulopathy without cardiac involvement. CASE PRESENTATION: A 33-year-old previously healthy male with no history of atopic disease presented with abdominal pain, hematochezia, peripheral eosinophilia as high as 10,000 eos/µL, right and left portal vein, mesenteric, and splenic vein thrombi with ischemic colitis resulting in hemicolectomy and small bowel resection. Despite an extensive workup for primary and secondary etiologies of hypereosinophilia by hematology/oncology, infectious disease, rheumatology and allergy/immunology, no other clear causes were identified, and the patient was diagnosed with idiopathic HES. His eosinophilia was successfully treated with high-dose oral corticosteroids (OCS) and subsequently transitioned to anti-IL-5-receptor therapy with benralizumab. He has continued this treatment for over a year with no recurrence of eosinophilia or thrombosis while on benralizumab. CONCLUSION: In patients with an unexplained coagulopathy and eosinophilia, eosinophilic disorders such as HES should be considered. Corticosteroid-sparing agents, such as benralizumab show promise for successfully treating these patients. BioMed Central 2022-03-22 /pmc/articles/PMC8941788/ /pubmed/35317854 http://dx.doi.org/10.1186/s13223-022-00666-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Aukstuolis, Kestutis
Cooper, Jocelyn J.
Altman, Katherine
Lang, Anna
Ayars, Andrew G.
Hypereosinophilic syndrome presenting as coagulopathy
title Hypereosinophilic syndrome presenting as coagulopathy
title_full Hypereosinophilic syndrome presenting as coagulopathy
title_fullStr Hypereosinophilic syndrome presenting as coagulopathy
title_full_unstemmed Hypereosinophilic syndrome presenting as coagulopathy
title_short Hypereosinophilic syndrome presenting as coagulopathy
title_sort hypereosinophilic syndrome presenting as coagulopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941788/
https://www.ncbi.nlm.nih.gov/pubmed/35317854
http://dx.doi.org/10.1186/s13223-022-00666-2
work_keys_str_mv AT aukstuoliskestutis hypereosinophilicsyndromepresentingascoagulopathy
AT cooperjocelynj hypereosinophilicsyndromepresentingascoagulopathy
AT altmankatherine hypereosinophilicsyndromepresentingascoagulopathy
AT langanna hypereosinophilicsyndromepresentingascoagulopathy
AT ayarsandrewg hypereosinophilicsyndromepresentingascoagulopathy